Alza's Doxil and Ethyol
Executive Summary
The Oncologic Drugs Advisory Committee will meet June 8 to discuss Doxil (liposomal doxorubicin) for the treatment of metastatic carcinoma of the ovaries in patients refractory to both paclitaxel and platinum-based chemotherapy and who may also be refractory to topotecan. The committee will meet in the afternoon of June 8 to review Alza/U.S. Bioscience's Ethyol (amifostine) for the reduction in incidence and severity of radiation-induced xerostomia. The meeting will begin at 8:00 a.m. at Town Center Hotel in Silver Spring, Md